These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer. Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050 [TBL] [Abstract][Full Text] [Related]
46. PMN and anti-tumor immunity--the case of bladder cancer immunotherapy. Brincks EL; Risk MC; Griffith TS Semin Cancer Biol; 2013 Jun; 23(3):183-9. PubMed ID: 23410637 [TBL] [Abstract][Full Text] [Related]
47. Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Ladel CH; Daugelat S; Kaufmann SH Eur J Immunol; 1995 Feb; 25(2):377-84. PubMed ID: 7875199 [TBL] [Abstract][Full Text] [Related]
48. Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG internalization into tumor cells. Ikeda N; Toida I; Iwasaki A; Kawai K; Akaza H Int J Urol; 2002 Jan; 9(1):29-35. PubMed ID: 11972647 [TBL] [Abstract][Full Text] [Related]
49. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy. Chang SG; Lee SJ; Huh JS; Lee JH Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036 [TBL] [Abstract][Full Text] [Related]
50. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002 [TBL] [Abstract][Full Text] [Related]
53. A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis. Rai PK; Chodisetti SB; Maurya SK; Nadeem S; Zeng W; Janmeja AK; Jackson DC; Agrewala JN J Transl Med; 2018 Oct; 16(1):279. PubMed ID: 30305097 [TBL] [Abstract][Full Text] [Related]
54. Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment. Langle YV; Balarino NP; Belgorosky D; Cresta Morgado PD; Sandes EO; Marino L; Bilbao ER; Zambrano M; Lodillinsky C; Eiján AM Nitric Oxide; 2020 May; 98():50-59. PubMed ID: 32147582 [TBL] [Abstract][Full Text] [Related]
55. Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. Naoe M; Ogawa Y; Takeshita K; Morita J; Iwamoto S; Miyazaki A; Yoshida H Int J Urol; 2007 Jun; 14(6):532-8; discussion 538. PubMed ID: 17593099 [TBL] [Abstract][Full Text] [Related]
56. Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer. Shariat SF; Enikeev DV; Mostafaei H Immunotherapy; 2019 Sep; 11(13):1083-1086. PubMed ID: 31385744 [No Abstract] [Full Text] [Related]
57. The immune responses of central and effector memory BCG-specific CD4+ T cells in BCG-vaccinated PPD+ donors were modulated by Treg cells. Li L; Qiao D; Zhang X; Liu Z; Wu C Immunobiology; 2011 Apr; 216(4):477-84. PubMed ID: 20950889 [TBL] [Abstract][Full Text] [Related]
58. An essential role for endogenous interferon-gamma in the generation of protective T cells against Mycobacterium bovis BCG in mice. Yang J; Mitsuyama M Immunology; 1997 Aug; 91(4):529-35. PubMed ID: 9378490 [TBL] [Abstract][Full Text] [Related]
59. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Takeuchi A; Dejima T; Yamada H; Shibata K; Nakamura R; Eto M; Nakatani T; Naito S; Yoshikai Y Eur J Immunol; 2011 Jan; 41(1):246-51. PubMed ID: 21182095 [TBL] [Abstract][Full Text] [Related]
60. Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Vekemans J; Amedei A; Ota MO; D'Elios MM; Goetghebuer T; Ismaili J; Newport MJ; Del Prete G; Goldman M; McAdam KP; Marchant A Eur J Immunol; 2001 May; 31(5):1531-5. PubMed ID: 11465110 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]